Masimo Corporation $MASI Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC decreased its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,193 shares of the medical equipment provider’s stock after selling 77 shares during the quarter. HB Wealth Management LLC’s holdings in Masimo were worth $201,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MASI. Durable Capital Partners LP acquired a new stake in Masimo during the first quarter worth $187,528,000. Massachusetts Financial Services Co. MA increased its stake in Masimo by 13.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider’s stock worth $327,842,000 after acquiring an additional 232,671 shares during the last quarter. Nuveen LLC acquired a new stake in Masimo during the first quarter worth $25,830,000. Alyeska Investment Group L.P. increased its stake in Masimo by 24.9% during the first quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock worth $120,374,000 after acquiring an additional 143,899 shares during the last quarter. Finally, Bank of Nova Scotia acquired a new stake in Masimo during the first quarter worth $15,528,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on MASI. Zacks Research raised Masimo from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Wall Street Zen cut Masimo from a “buy” rating to a “hold” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Saturday, September 27th. Piper Sandler lifted their price objective on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $198.00 price objective on shares of Masimo in a research note on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $194.60.

Masimo Stock Up 1.4%

Shares of NASDAQ MASI opened at $150.25 on Wednesday. The company has a market capitalization of $8.16 billion, a price-to-earnings ratio of -17.63 and a beta of 1.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. The business has a 50-day moving average of $146.32 and a two-hundred day moving average of $155.63. Masimo Corporation has a 1 year low of $133.70 and a 1 year high of $194.88.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.11. The company had revenue of $370.90 million during the quarter, compared to the consensus estimate of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.Masimo’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.86 EPS. On average, analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In other Masimo news, Director William R. Jellison purchased 3,000 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was bought at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.90% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.